Completed PHASE3 INTERVENTIONAL 2-arm NCT00309478

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

A Randomized Phase III Study Comparing Cyclophosphamide + Methotrexate + Fluorouracil vs. Goserelin + Tamoxifen in Premenopausal, Hormone Receptor-positive, Lymph Node-positive or -Negative Patients

Sponsor: AstraZeneca

Conditions Early-stage Breast Cancer

Interventions Cyclophosphamide Fluorouracil implant Goserelin Methotrexate Tamoxifen

Updated 7 times since 2017 Last updated: Jun 28, 2023 Started: Dec 31, 1990 Primary completion: Jun 30, 2004 Completion: Jun 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Early-stage Breast Cancer, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 1990. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jul 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2023 [monthly]

Completed PHASE3
Nov 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 1990

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Austrian Breast & Colorectal Cancer Study Group

Data source: Austrian Breast & Colorectal Cancer Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.